Skip to main content
. Author manuscript; available in PMC: 2012 Jun 14.
Published in final edited form as: Cancer Cell. 2011 Jun 14;19(6):715–727. doi: 10.1016/j.ccr.2011.04.016

Figure 1. Diverse tumor-derived chemoattractants promote myeloid cell trafficking to tumors.

Figure 1

(A) Left, CD11b+ pixels/field in normal human and murine breast and invasive ductal breast carcinoma, normal mouse pancreas and orthotopic Panc02 pancreatic carcinoma, and normal murine lung and orthotopic LLC (n=6–10), *p<0.001 vs normal tissue. Right, CD11b+ cells (red, arrowheads) and nuclei (blue) in normal murine and human breast and invasive ductal carcinoma; scale bars, 40 μm. (B) Graphs, quantification of myeloid (CD11b) and endothelial (CD31) cells over time in LLC tumors, *p<0.05 (n=10). Images, LLC tumor sections immunostained to detect myeloid (CD11b) and endothelial (CD31) cells; scale bars, 40 μm. (C) Flow cytometric quantification of Gr1+CD11b myeloid cells in tumors (n=3). Tumor-derived myeloid cells are comprised primarily of Gr1lo/negCD11b+F4/80+CD14+MHCII+ monocyte/macrophages. (E) Relative levels of chemoattractant gene expression in CD11b+ myeloid cells and CD11b- tumor cells from 14d orthotopic LLC tumors (n=4), *p<0.05 vs normal lung. (F) SDF-1α and IL-1β protein expression in tumor-derived CD11b+ myeloid and tumor cells from 14d LLC tumors (n=3), *p<0.05. See also Figure S1.